Tech Company Financing Transactions
Celularity Funding Round
On 2/16/2018, Celularity raised $250 million in funding from private investors, Celgene and Human Longevity.
Transaction Overview
Company Name
Announced On
2/16/2018
Transaction Type
Venture Equity
Amount
$250,000,000
Round
Undisclosed
Investors
private investors (Lead Investor) (Bob Hariri)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
33 Technology Dr.
Warren, NJ 07059
USA
Warren, NJ 07059
USA
Phone
Website
Email Address
Overview
Celularity is a biotechnology company productizing allogeneic cells and tissues derived from the postpartum placenta. These materials have the ability to augment our immunity and longevity by amplifying the body's ability to fight disease, heal, and regenerate itself.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bob Hariri
Chief Financial Officer
David Lemus
Chief Medical Officer
Nassir Habboubi
Chief Scientific Officer
Xiaokui Zhang
VP - Administration
John Haines
VP - Human Resources
Beth Steinbrenner
Browse more venture capital transactions:
Prev: 2/16/2018: Octagon Therapeutics venture capital transaction
Next: 2/16/2018: Dwolla venture capital transaction
Share this article
About Database of VC Transactions
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs